Text Size

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication

Uusitalo H., Chen E., Pfeiffer N., Brignole-Baudouin F., Kaarniranta K., Leino M., Puska P., Palmgren E., Hamacher T., Hofmann G., Petzold G., Richter U., Riedel T., Winter M., Ropo A.


  • 2010
  • Acta Ophthalmologica
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    University of Tampere, Tampere University Hospital, Tampere, Finland; St Erik Eye Hospital, Stockholm, Sweden; Augenklinik der Joh.-Gutenberg- Universität Mainz, Mainz, Germany; Department of Toxicology, University Paris Descartes, University Paris 6, Paris, France; University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland; Kuopion Näkökeskus, Kuopio, Finland; Helsingin Lääkärikeskus, Helsinki, Finland; Nyköpings Lasarett, Nyköping, Sweden; Praxis Starnberg, Starnberg, Germany; Praxis Schweinfurt, Schweinfurt, Germany; Praxis Kulmbach, Kulmbach, Germany; Praxis Regensburg, Regensburg, Germany; Praxis Dresden, Dresden, Germany; Praxis Bremen, Bremen, Germany; Santen Oy, Tampere, Finland

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.


Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.


Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022